CRMD241220P2000
- 0.15
- 0.000.00%
CorMedix Newsroom
CorMedix Set for Market Growth With Policy Changes and Strategic Partnerships Boosting DefenCath Adoption
CorMedix Inc. Supports CMS Policy Updates Regarding Access to Innovative Drug Products
CORMEDIX INC. SUPPORTS CMS POLICY UPDATES REGARDING ACCESS TO INNOVATIVE DRUG PRODUCTS
CorMedix Approves Key Governance and Incentive Changes
Here's Why We Think CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Looks Fair for the Time Being
CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium
Rainbows and Unicorns: CorMedix Inc. (NASDAQ:CRMD) Analysts Just Became A Lot More Optimistic
CorMedix Inc. (NASDAQ:CRMD) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates
While Shareholders of CorMedix (NASDAQ:CRMD) Are in the Black Over 1 Year, Those Who Bought a Week Ago Aren't so Fortunate
Truist Financial Maintains CorMedix(CRMD.US) With Buy Rating
Cormedix Analyst Ratings
Express News | CorMedix Inc : RBC Raises Target Price to $11 From $9
Q3 2024 CorMedix Inc Earnings Call
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Raises Target Price to $18
CorMedix Inc. (CRMD) Q3 2024 Earnings Call Transcript Summary
12 Health Care Stocks Moving In Wednesday's Intraday Session
JMP Securities Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $19
CorMedix Down Over 15%, On Pace for Largest Percent Decrease Since June 2023 -- Data Talk
CorMedix Shares Are Trading Lower. The Company Reported Q3 Financial Results.
CorMedix | 10-Q: Q3 2024 Earnings Report